Migraine - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 219 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Migraine - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Migraine - Pipeline Review, H1 2016', provides an overview of the Migraine pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Migraine
- The report reviews pipeline therapeutics for Migraine by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Migraine therapeutics and enlists all their major and minor projects
- The report assesses Migraine therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Migraine

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Migraine
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 6
Migraine Overview 7
Therapeutics Development 8
Migraine - Therapeutics under Development by Companies 10
Migraine - Therapeutics under Investigation by Universities/Institutes 14
Migraine - Pipeline Products Glance 15
Migraine - Products under Development by Companies 19
Migraine - Products under Investigation by Universities/Institutes 23
Migraine - Companies Involved in Therapeutics Development 24
Migraine - Therapeutics Assessment 63
Drug Profiles 78
Migraine - Recent Pipeline Updates 164
Migraine - Dormant Projects 194
Migraine - Discontinued Products 200
Migraine - Product Development Milestones 201
Appendix 210

List of Tables

Number of Products under Development for Migraine, H1 2016 16
Number of Products under Development for Migraine - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Comparative Analysis by Late Stage Development, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 24
Comparative Analysis by Early Stage Development, H1 2016 25
Comparative Analysis by Unknown Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2016 31
Migraine - Pipeline by Achelios Therapeutics, Inc., H1 2016 32
Migraine - Pipeline by Acorda Therapeutics, Inc., H1 2016 33
Migraine - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 34
Migraine - Pipeline by Alder Biopharmaceuticals Inc., H1 2016 35
Migraine - Pipeline by Allergan Plc, H1 2016 36
Migraine - Pipeline by Amgen Inc., H1 2016 37
Migraine - Pipeline by Aralez Pharmaceuticals Inc., H1 2016 38
Migraine - Pipeline by Astellas Pharma Inc., H1 2016 39
Migraine - Pipeline by Biofrontera AG, H1 2016 40
Migraine - Pipeline by Bristol-Myers Squibb Company, H1 2016 41
Migraine - Pipeline by Charleston Laboratories, Inc., H1 2016 42
Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2016 43
Migraine - Pipeline by Corium International, Inc., H1 2016 44
Migraine - Pipeline by D-Pharm Ltd., H1 2016 45
Migraine - Pipeline by Eli Lilly and Company, H1 2016 46
Migraine - Pipeline by iCeutica, Inc., H1 2016 47
Migraine - Pipeline by Impel NeuroPharma, Inc., H1 2016 48
Migraine - Pipeline by Klaria Pharma Holding AB, H1 2016 49
Migraine - Pipeline by Mallinckrodt Plc, H1 2016 50
Migraine - Pipeline by Medestea Research & Production S.p.A., H1 2016 51
Migraine - Pipeline by Merck & Co., Inc., H1 2016 52
Migraine - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 53
Migraine - Pipeline by Monosol Rx, LLC, H1 2016 54
Migraine - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 55
Migraine - Pipeline by Noxxon Pharma AG, H1 2016 56
Migraine - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 57
Migraine - Pipeline by Pivot Pharmaceuticals Inc, H1 2016 58
Migraine - Pipeline by Promius Pharma, LLC, H1 2016 59
Migraine - Pipeline by RedHill Biopharma Ltd., H1 2016 60
Migraine - Pipeline by Revance Therapeutics, Inc., H1 2016 61
Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2016 62
Migraine - Pipeline by Suda Ltd, H1 2016 63
Migraine - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 64
Migraine - Pipeline by TheraJect, Inc., H1 2016 65
Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 66
Migraine - Pipeline by Trevena, Inc., H1 2016 67
Migraine - Pipeline by Trigemina, Inc., H1 2016 68
Migraine - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 69
Migraine - Pipeline by Zosano Pharma Corporation, H1 2016 70
Assessment by Monotherapy Products, H1 2016 71
Assessment by Combination Products, H1 2016 72
Number of Products by Stage and Target, H1 2016 74
Number of Products by Stage and Mechanism of Action, H1 2016 79
Number of Products by Stage and Route of Administration, H1 2016 83
Number of Products by Stage and Molecule Type, H1 2016 85
Migraine Therapeutics - Recent Pipeline Updates, H1 2016 172
Migraine - Dormant Projects, H1 2016 202
Migraine - Dormant Projects (Contd..1), H1 2016 203
Migraine - Dormant Projects (Contd..2), H1 2016 204
Migraine - Dormant Projects (Contd..3), H1 2016 205
Migraine - Dormant Projects (Contd..4), H1 2016 206
Migraine - Dormant Projects (Contd..5), H1 2016 207
Migraine - Discontinued Products, H1 2016 208